BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 21835143)

  • 21. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.
    Weinstein LS; Shenker A; Gejman PV; Merino MJ; Friedman E; Spiegel AM
    N Engl J Med; 1991 Dec; 325(24):1688-95. PubMed ID: 1944469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
    Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
    Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of Rare Somatic GNAS Mutation in McCune-Albright Syndrome Using a Novel Peptide Nucleic Acid Probe in a Single Tube.
    Lo FS; Chen TL; Chiou CC
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29104223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GNAS mutation as an alternative mechanism of activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type.
    Nomura R; Saito T; Mitomi H; Hidaka Y; Lee SY; Watanabe S; Yao T
    Hum Pathol; 2014 Dec; 45(12):2488-96. PubMed ID: 25288233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic and molecular aspects of McCune-Albright syndrome.
    Lietman SA; Schwindinger WF; Levine MA
    Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():380-5. PubMed ID: 17982384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic utility of the GNAS mutation in patients with fibrous dysplasia: meta-analysis of 168 sporadic cases.
    Lee SE; Lee EH; Park H; Sung JY; Lee HW; Kang SY; Seo S; Kim BH; Lee H; Seo AN; Ahn G; Choi YL
    Hum Pathol; 2012 Aug; 43(8):1234-42. PubMed ID: 22245114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations.
    Almeida MQ; Azevedo MF; Xekouki P; Bimpaki EI; Horvath A; Collins MT; Karaviti LP; Jeha GS; Bhattacharyya N; Cheadle C; Watkins T; Bourdeau I; Nesterova M; Stratakis CA
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E687-93. PubMed ID: 22259056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of GNAS R201H substitution mutation in polyostotic fibrous dysplasia: Pyrosequencing analysis in tissue samples with or without decalcification.
    Shin SJ; Lee SJ; Kim SK
    Sci Rep; 2017 Jun; 7(1):2836. PubMed ID: 28588314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations.
    Matsubara A; Sekine S; Ogawa R; Yoshida M; Kasamatsu T; Tsuda H; Kanai Y
    Am J Surg Pathol; 2014 Mar; 38(3):370-6. PubMed ID: 24145653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. McCune Albright syndrome and bilateral adrenal hyperplasia: the GNAS mutation may only be present in adrenal tissue.
    Angelousi A; Fencl F; Faucz FR; Malikova J; Sumnik Z; Lebl J; Stratakis CA
    Hormones (Athens); 2015; 14(3):447-50. PubMed ID: 26188235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management.
    Shanbhogue AK; Prasad SR; Takahashi N; Vikram R; Sahani DV
    Radiology; 2011 Mar; 258(3):673-93. PubMed ID: 21339346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome.
    Vortmeyer AO; Gläsker S; Mehta GU; Abu-Asab MS; Smith JH; Zhuang Z; Collins MT; Oldfield EH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2404-13. PubMed ID: 22564667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subtype classification of hepatocellular adenoma.
    Bioulac-Sage P; Balabaud C; Zucman-Rossi J
    Dig Surg; 2010; 27(1):39-45. PubMed ID: 20357450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics of PRKACA mutations in Chinese patients with adrenal lesions: a single-centre study.
    Li X; Wang B; Tang L; Lang B; Zhang Y; Zhang F; Chen L; Ouyang J; Zhang X
    Clin Endocrinol (Oxf); 2016 Dec; 85(6):954-961. PubMed ID: 27296931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway.
    Pilati C; Zucman-Rossi J
    Cytokine Growth Factor Rev; 2015 Oct; 26(5):499-506. PubMed ID: 26188635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission.
    Freda PU; Chung WK; Matsuoka N; Walsh JE; Kanibir MN; Kleinman G; Wang Y; Bruce JN; Post KD
    Pituitary; 2007; 10(3):275-82. PubMed ID: 17594522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain.
    Palos-Paz F; Perez-Guerra O; Cameselle-Teijeiro J; Rueda-Chimeno C; Barreiro-Morandeira F; Lado-Abeal J; ; Araujo Vilar D; Argueso R; Barca O; Botana M; Cabezas-Agrícola JM; Catalina P; Dominguez Gerpe L; Fernandez T; Mato A; Nuño A; Penin M; Victoria B
    Eur J Endocrinol; 2008 Nov; 159(5):623-31. PubMed ID: 18694911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.
    Margolskee E; Bao F; de Gonzalez AK; Moreira RK; Lagana S; Sireci AN; Sepulveda AR; Remotti H; Lefkowitch JH; Salomao M
    Diagn Pathol; 2016 Mar; 11():27. PubMed ID: 26961851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
    Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
    Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon.
    Putra J; Ferrell LD; Gouw ASH; Paradis V; Rishi A; Sempoux C; Balabaud C; Thung SN; Bioulac-Sage P
    Mod Pathol; 2020 Apr; 33(4):665-675. PubMed ID: 31570768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.